New Alzheimer's treatments
Dementia information
Two new medicines, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease.
In this section:
These are known as disease-modifying treatments and have been licensed for private use in the UK. Other medicines are under review to see if they could be prescribed to people in the very early stages of Alzheimer’s, when the treatments are most effective.
Beyond lecanemab and donanemab, there are over 100 other drugs for different types of dementia currently in clinical trials.
When people can be diagnosed in the earlier stages of dementia and access new disease-modifying treatments, the typical pattern of decline experienced by those living with dementia could be changed.
By treating someone before noticeable symptoms start to happen, these medicines could give people with early-stage Alzheimer’s more time to live an independent life.
However, before a new disease-modifying treatment can be approved for use, it would have to show that it works to improve or maintain a person’s ability to carry out daily tasks.
Symptomatic drug treatments vs disease-modifying treatments
| Symptomatic treatments for dementia | Disease-modifying treatments for dementia |
|---|---|
| Available in the UK | Two Alzheimer's drugs (lecanemab and donanemab) are available in certain private clinics in the UK. They are not available on the NHS |
| Can stabilise or slightly improve a person’s symptoms, often their memory and thinking problems | Designed to slow the progression of a disease that causes dementia, and slow down the speed that symptoms get worse |
| Can help them maintain their ability to carry out everyday tasks, making a big difference to their quality of life | Aim to maintain a person’s ability to carry out daily tasks |
| Side effects can include headaches, constipation or diarrhoea, and tiredness | Side effects can include amyloid-related imaging abnormalities (ARIA), which are areas of brain swelling or bleeds |
| Don't work well for everyone. Also don’t continue to work effectively once a person’s dementia becomes more severe | Don't work well for everyone. No evidence about long-term effect over many years yet |
| Beneficial effects only last for around a year or two | Preserve a person’s ability to function independently for longer |
| Do not stop the disease from progressing and damaging more brain over time | Not a cure, but a positive first step towards changing the lives of people affected |
Below you can hear from Rita, whose husband Larry lives with mild cognitive impairment and is taking part in a lecanemab trial. She reflects on what this progress means for people affected by dementia.
Research suggests that new disease-modifying treatments will have the most beneficial effect when given to people in the very early stages of dementia.
This is when someone goes to their doctor and they are diagnosed with mild cognitive impairment (MCI) or very early stage dementia. This means that early diagnosis is key to the success of new emerging treatments, and the two go hand in hand.
Find out more about how our researchers are working hard to find new treatments and improve early diagnosis so that people living with dementia can keep more of their independence and still enjoy daily activities.
The Alzheimer’s drugs, lecanemab and donanemab, have proved what we’ve always known – that, through research, we can slow down the diseases that cause dementia.
But we won’t stop there. With your support, we will keep going until everyone is free from the heartbreak of dementia – that means finding a cure.
You can find out more about emerging treatments on our explainers about donanemab and lecanemab.
Find out more
You can find out more about current diagnosis and treatments for each type of dementia on the following pages:
Order health information
Alzheimer's Research UK has a wide range of information about dementia. Order booklets or download them from our online form.
Complete the survey
Was this information helpful?
Let us know what you think by filling out this short survey.
Downloads
Dementia information
Read more about treatments for dementia, including information on treating depression, anxiety and agitation and for information on antipsychotics.
-
PDF, 5.82 MB, 15 pages
This information is currently under review. It was written by Alzheimer's Research UK's Information Services team with input from lay and expert reviewers. Please get in touch if you'd like a referenced copy.
This information is produced with support from The Perfume Shop who had no input into the content.
